
Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
The combination of relacorilant and nab-paclitaxel (Abraxane) generated a progression-free survival (PFS) benefit compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, meeting the primary end point of the phase 3 ROSELLA …